348622-98-0

Basic information

• Product Name: ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate
• Synonyms: ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate
• CAS NO: 348622-98-0
• Molecular Weight: 394.511
• Mol File: 348622-98-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate(348622-98-0)
• EPA Substance Registry System: ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate(348622-98-0)

Safety Data

• Hazardous Substances Data: 348622-98-0(Hazardous Substances Data)

Upstream product

• 349094-99-1 C₂₁H₃₆N₂O₆ 

Downstream Products

• 348622-99-1 (3R)-6-cyclohexyl-3-[3-(ethoxycarbonyl)-1,2,4-oxadiazol-5-yl]hexanoic acid 
• 348624-70-4 (3R)6-Cyclohexyl-N-hydroxy-3-[3-(1H-imidazol-2-ylmethyl)-1,2,4-oxadiazol-5-yl]hexanamide 

Relevant articles and documents

Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents

Succinyl hydroxamates 1 and 2 are disclosed as novel series of potent and selective inhibitors of procollagen C-proteinase (PCP) which may have potential as anti-fibrotic agents. Carboxamide 7 demonstrated good PCP inhibition and had excellent selectivity

3-heterocyclylpropanohydroxamic acid PCP inhibitors

Compounds of formula (I) and their salts, solvates and prodrugs, wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

PROCOLLAGEN C-PROTEINASE INHIBITORS

and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.